Skip to main content

Advertisement

Log in

Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative radioimmunotherapy using 131I-rituximab in previously heavily treated patients with B-cell non-Hodgkin’s lymphoma (B-NHL).

Methods

Nine patients with relapsed, refractory or transformed B-NHL received ten radioimmunotherapies. Patients had a median of 5 (range 2–7) prior standard therapies. Four patients had received prior high-dose chemotherapy followed by autologous stem cell transplantation, and eight had received prior rituximab therapy. Histopathology consisted of four mantle cell, one follicular and four diffuse large B-cell lymphomas. Rituximab, a monoclonal chimeric anti-CD20 antibody (IDEC-C2B8), was labelled with 131I using the Iodogen method. The administered activity (2,200±600 MBq) was based on a dosimetrically calculated 45 cGy total-body radiation dose. All patients received an infusion of 2.5 mg/kg of rituximab prior to administration of the radiopharmaceutical.

Results

No acute adverse effects were observed after the administration of 131I-rituximab. Radioimmunotherapy was safe in our patient group and achieved one complete response ongoing at 14 months and two partial responses progressing at 12 and 13 months after treatment. One partial responder was re-treated with radioimmunotherapy and achieved an additional progression-free interval of 7 months. Four non-responders with bulky disease died 4.8±2.0 months after therapy. Three patients had an elevated serum lactate dehydrogenase (LDH) level prior to radioimmunotherapy and none of the patients responded. Of two patients who received radioimmunotherapy as an additional treatment after salvage chemotherapy, one continues to be disease-free at 9 months and one relapsed at 5 months’ follow-up. Reversible grade 3 or 4 haematological toxicity occurred in seven of nine patients. Median nadirs were 35 days for platelets, 44 days for leucocytes and 57 days for erythrocytes.

Conclusion

Radioimmunotherapy with 131I-rituximab in previously heavily treated B-NHL patients was safe and well tolerated, and four out of ten therapies induced responses. Radioimmunotherapy was less efficient in patients with bulky disease and elevated LDH. Severe haematological toxicity in seven patients did not cause significant clinical problems. Radioimmunotherapy seems to be an additional therapeutic option in carefully selected therapy-refractory B-NHL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1023–30.

    Article  CAS  PubMed  Google Scholar 

  2. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470–80.

    CAS  PubMed  Google Scholar 

  3. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–33.

    CAS  PubMed  Google Scholar 

  4. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268–76.

    CAS  PubMed  Google Scholar 

  5. Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004;72:10–7.

    Article  PubMed  Google Scholar 

  6. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004;5:341–53.

    Article  PubMed  Google Scholar 

  7. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Pract 1998;6:195–7.

    Google Scholar 

  8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42.

    Article  CAS  PubMed  Google Scholar 

  9. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, et al. Treatment of refractory non-Hodgkin’s lymphoma with radiolabelled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027–38.

    CAS  PubMed  Google Scholar 

  10. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labelled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696–711.

    CAS  PubMed  Google Scholar 

  11. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219–24.

    Article  CAS  PubMed  Google Scholar 

  12. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:2453–63.

    Article  CAS  PubMed  Google Scholar 

  13. Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Behe M, et al. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999;5:3304s–14s.

    CAS  PubMed  Google Scholar 

  14. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labelled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94:1363–72.

    Google Scholar 

  15. Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, et al. Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276–82.

    Article  CAS  PubMed  Google Scholar 

  16. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin’s lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Biother Radiopharm 2003;18:513–24.

    Article  CAS  Google Scholar 

  17. Behr TM, Gotthardt M, Becker W, Behe M. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin 2002;41:71–9.

    CAS  PubMed  Google Scholar 

  18. Wahl RL, Wissing J, del Rosario R, Zasadny KR. Inhibition of autoradiolysis of radiolabelled monoclonal antibodies by cryopreservation. J Nucl Med 1990;31:84–9.

    CAS  PubMed  Google Scholar 

  19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.

    CAS  PubMed  Google Scholar 

  20. Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39:21S–27S.

    CAS  PubMed  Google Scholar 

  21. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974–81.

    CAS  PubMed  Google Scholar 

  22. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259–66.

    CAS  PubMed  Google Scholar 

  23. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol 2003;21:1263–70.

    Article  CAS  PubMed  Google Scholar 

  24. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000;27:766–77.

    Article  CAS  PubMed  Google Scholar 

  25. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, et al. Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with zevalin, a 90Y-labelled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5:3281s–6s.

    CAS  PubMed  Google Scholar 

  26. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:3262–9.

    Article  CAS  PubMed  Google Scholar 

  27. Press OW. Radiolabelled antibody therapy of B-cell lymphomas. Semin Oncol 1999;26:58–65.

    CAS  PubMed  Google Scholar 

  28. Goldenberg DM. Advancing role of radiolabelled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281–96.

    Google Scholar 

  29. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999;17:3793–803.

    CAS  PubMed  Google Scholar 

  30. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587–94.

    CAS  PubMed  Google Scholar 

  31. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al. Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 1998;16:3246–56.

    CAS  PubMed  Google Scholar 

  32. Nordoy T, Kolstad A, Tuck MK, Aaberge IS, Husebekk A, Kaminski MS. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin’s B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 2001;100:40–8.

    Article  CAS  PubMed  Google Scholar 

  33. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336–40.

    Article  CAS  PubMed  Google Scholar 

  34. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labelled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maren Bienert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bienert, M., Reisinger, I., Srock, S. et al. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience. Eur J Nucl Med Mol Imaging 32, 1225–1233 (2005). https://doi.org/10.1007/s00259-005-1770-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1770-7

Keywords

Navigation